Media

November, 2019, an article in MIRROR REVIEW was published "4HF BIOTEC: A Novel Approach For Cancer Treatment".

                https://www.mirrorreview.com/4hf-biotec-novel-approach-cancer-treatment/

-----------------------------------

 

October 26 - 30, 2019, 4HF Biotec presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston

Posters :

 

# C075 - “The use of 4HF Cancer Data Miner platform for an In Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib”

Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Session Date: Tuesday, October 29 -12.30 -16 PM

 

# C060 – “Broad spectrum activity of the MDM2 inhibitor MI-773 in hematologic and solid cancer cell lines in-vitro and determination of predictive biomarkers”

Session Title: Therapeutic Agents-- Other
Session Date: Tuesday, October 29 -12.30 -16 PM

 

-----------------------------------

 

October 8 -11, 2019, 4HF Biotec presented in collaboration with Bionavigen at 10th Annual World ADC, San Diego

Poster entitled :

#01 - "4HF Cancer Data Miner platform for an accelerated

In Silico ADC target discovery and evaluation"

-----------------------------------
 

July 2019, StartupCity selected 4HF Biotec in the top 15 most promising Biotec startups in Europe

Links:

https://biotech-europe.startupcity.com/vendors/top-biotech-startups-in-europe-2019.html

https://biotech-europe.startupcity.com/vendor/4hf-biotec-bringing-forth-novel-anticancer-drugs-cid-290-mid-34.html

-----------------------------------

18th July 20194HF Biotec announced that it entered into a collaboration with Bionavigen in the field of target and drug discovery.

-----------------------------------

Mar 2019, 4HF participated at the AACR ANNUAL MEETING 2019, Mar 29-Apr 3, Atlanta, United States.

 

Our posters: Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers. Abstract nr 2196.

 

and,

 

Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers. Abstract nr 3074.

                                                 ------------------------------------

Nov 2018, 4HF Biotec participated at the 30th EORTC-NCI-AACR SYMPOSIUM : Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that took place 13-16 Nov, Dublin, Ireland.

 

Our poster: #PB-039, Title : Broad spectrum activity of Sabutoclax in haematological and solid cancer cell lines is associated with defined biomarkers. Section "Molecular Targeted Agents" on 13 November 2018.

------------------------------------

Apr 2018, 4HF Biotec will participate at the AACR Annual Meeting 2018 April 14-18,  Chicago, Illinois, USA.

                                                 -----------------------------------

Mar 2018, 4HF Biotec participated at the World ADC 2018, 26–28 March, Berlin, Germany.

------------------------------------

Feb 2018, 4HF Biotec participated at the 39th EORTC-PAMM Winter Meeting; 7-10 Feb, Roma, Italy.

-----------------------------------

Oct 2017, 4HF Biotec participated at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that took place October 26-30, 2017,  Philadelphia, Pennsylvania.

 

We took this opportunity to present our poster #B167, entitled : ”KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 Inhibitor”  October 29, 2017, 12:30 - 4:00 PM, Hall E.